Biotech News

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Protagenic Therapeutics (PTIX)Protagenic Therapeutics2026-05-19 08:15 ESTCompany update

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting,...

Related news

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

ADXNAddex Therapeutics2026-09-28 05:00 EST

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

ADXNAddex Therapeutics2026-09-24 05:00 EST

Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

View all latest news

Protagenic Therapeutics

Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.

Recent company news

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

PTIXProtagenic Therapeutics2026-03-17 08:00 EST

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

PTIXProtagenic Therapeutics2026-03-10 08:00 EST

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

PTIXProtagenic Therapeutics2025-12-09 08:46 EST

Results from Phase 1 Multiple-Dose Study of PT00114

Stock data

Close: 0.63 USD
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States